Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.01T
Market cap1.01T
Price-Earnings ratio
45.31
Price-Earnings ratio45.31
Dividend yield
0.58%
Dividend yield0.58%
Average volume
4.38M
Average volume4.38M
High today
$1,064.33
High today$1,064.33
Low today
$1,033.82
Low today$1,033.82
Open price
$1,040.94
Open price$1,040.94
Volume
2.70M
Volume2.70M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.01T, Eli Lilly(LLY) trades at $1,041.51. The stock has a price-to-earnings ratio of 45.31 and currently yields dividends of 57.7%.

On 2026-02-15, Eli Lilly(LLY) stock moved within a range of $1,033.82 to $1,064.33. With shares now at $1,041.51, the stock is trading +0.7% above its intraday low and -2.1% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 2.7M, versus its average volume of 4.38M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

The Motley Fool 1d
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?

Eli Lilly continues to pursue smart acquisitions for the long term. The pharmaceutical industry can be a tricky investment. Remember Pfizer (PFE +0.38%) back i...

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?
Simply Wall St 2d
How Lilly’s GLP-1 Momentum, Orforglipron Launch and Orna Deal Could Shape Eli Lilly Investors

Eli Lilly recently reported past fourth-quarter 2025 and full-year results showing higher sales and net income, issued 2026 revenue guidance of US$80.00 billion...

How Lilly’s GLP-1 Momentum, Orforglipron Launch and Orna Deal Could Shape Eli Lilly Investors
TipRanks 2d
Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The RENEW-Scz-1 trial is a Phase 2 study from Eli Lilly and Company that tests...

Analyst ratings

78%

of 32 ratings
Buy
78.1%
Hold
18.8%
Sell
3.1%

More LLY News

TipRanks 2d
Roche’s New Breast Cancer Trial Pits Its Pipeline Against Eli Lilly’s Standard: What It Means for RHHBY

Roche Holding AG (RHHBY) announced an update on their ongoing clinical study. Roche Steps Up in ER+ Breast Cancer: What Investors Should Know This new Genente...

TipRanks 2d
Eli Lilly has built $1.5B worth of inventory of orforglipron, Reuters says

Eli Lilly (LLY) has built $1.5B worth of pre-launch inventory of orforglipron, the company’s experimental oral weight-loss drug, ahead of the U.S. Food and Drug...

Benzinga 3d
Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms

Eli Lilly and Company (NYSE:LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulato...

Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms
Simply Wall St 3d
Eli Lilly Uses GLP 1 Cash Flows To Pursue Next Wave RNA Therapies

Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics, a company focused on circular RNA based medicines. The deal brings Orna's in vivo cel...

Eli Lilly Uses GLP 1 Cash Flows To Pursue Next Wave RNA Therapies
TipRanks 3d
Eli Lilly Stock Gets New ‘Buy Rating’ After Strong Earnings

Eli Lilly’s stock (LLY) has received a new Buy rating following recent financial results that blew past Wall Street forecasts. Ilya Zubkov, an analyst at Freed...

Zacks 3d
The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...

The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific
Nasdaq 4d
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.

Key Points Eli Lilly and Novo Nordisk dominate the weight loss drug market, one that soon may approach $100 billion. One of these players has recently gained...

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.